imiquimod has been researched along with Dermatitis, Atopic in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Im, DS; Son, SE | 1 |
| Fujimoto, M; Fujisawa, Y; Ichimura, Y; Ishitsuka, Y; Kubota, N; Mizuno, S; Nakamura, Y; Okiyama, N; Saito, A; Takahashi, S; Tanaka, R; Watanabe, R | 1 |
| Bernard, FX; Bodet, C; Buffière-Morgado, A; Camus, M; Couderc, E; Favot, L; Garcia, M; Guillet, G; Huguier, V; Jégou, JF; Lacombe, C; Lecron, JC; Levillain, P; Mcheik, J; Morel, F; Paquier, C; Pohin, M; Yssel, H | 1 |
| Cao, J; Dang, E; Fu, M; Jin, B; Li, W; Liu, Y; Wang, G; Xiao, C; Yao, X; Zhang, C; Zhu, Z | 1 |
| Haba, R; He, YY; Katsuki, N; Kubota, Y; Kushida, Y; Moriue, T; Nakai, K; Naruse, F; Nishiyama, F; Yoneda, K | 1 |
| Haba, R; Kubota, Y; Kushida, Y; Nakai, K | 1 |
| Pink, AE; Smith, CH; Storan, ER; Woolf, RT | 1 |
| Honda, K; Lee, HC; Ohba, M; Okuno, T; Takahashi, N; Takamori, K; Tominaga, M; Yasukawa, K; Yokomizo, T | 1 |
| Dainichi, T; Hirakawa, S; Honda, T; Kabashima, K; Kitoh, A; Miyachi, Y; Nakajima, S; Nakashima, C; Nonomura, Y; Otsuka, A; Wong, LS; Yamamoto, Y | 1 |
| Hopp, S; Quest, TL; Wanat, KA | 1 |
| Barling, A; Coussens, LM; De La Torre, R; Ding, H; Hanifin, J; Hornick, N; Kulesz-Martin, M; Liu, Y; Simpson, E; Swanzey, E; Tsujikawa, T; Wang, Y; Wang, Z; Wortham, A | 1 |
| Aber, C; Kirsner, RS | 1 |
| Hengge, UR; Meykadeh, N | 1 |
| Ambach, A; Bonnekoh, B; Gollnick, H; Nguyen, M; Schön, MP | 1 |
| Sidbury, R | 1 |
| Skinner, R | 1 |
| Sauder, DN | 1 |
| Djawari, D | 1 |
4 review(s) available for imiquimod and Dermatitis, Atopic
| Article | Year |
|---|---|
Infectious Disease Practice Gaps in Dermatology.
Topics: Acne Vulgaris; Adjuvants, Immunologic; Aminoquinolines; Anti-Bacterial Agents; Antifungal Agents; Dermatitis, Atopic; Dermatology; Humans; Imiquimod; Immunosuppressive Agents; Molluscum Contagiosum; Onychomycosis; Reagent Kits, Diagnostic; Skin Diseases, Infectious; Soft Tissue Infections; Vaccination | 2016 |
What's new in pediatric dermatology: update for the pediatrician.
Topics: Adjuvants, Immunologic; Aminoquinolines; Child; Clinical Trials as Topic; Dermatitis, Atopic; Hemangioma; Humans; Imiquimod; Immunoglobulins; Immunologic Factors; Immunosuppressive Agents; Infant; Molluscum Contagiosum; Skin; Skin Diseases; Stevens-Johnson Syndrome; Tacrolimus; Vitiligo; Warts | 2004 |
Role of topical therapies in the management of cutaneous disease.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Condylomata Acuminata; Dermatitis, Atopic; Dermatitis, Seborrheic; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis; Melanoma; Membrane Glycoproteins; Receptors, Cell Surface; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Toll-Like Receptors | 2004 |
Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.
Topics: Adjuvants, Immunologic; Alefacept; Aminoquinolines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcineurin Inhibitors; CD11 Antigens; Dermatitis, Atopic; Glucocorticoids; Humans; Imiquimod; Interferons; Membrane Glycoproteins; Mycophenolic Acid; Psoriasis; Receptors, Cell Surface; Recombinant Fusion Proteins; Skin Diseases; Tacrolimus; Toll-Like Receptors | 2004 |
14 other study(ies) available for imiquimod and Dermatitis, Atopic
| Article | Year |
|---|---|
Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Benzoates; Cell Differentiation; Dermatitis, Atopic; Humans; Imiquimod; PPAR gamma; Psoriasis; Skin; Telmisartan; Th17 Cells | 2023 |
Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses.
Topics: Animals; Antigen Presentation; B7-H1 Antigen; Calcitriol; Cells, Cultured; Cytokines; Dendritic Cells; Dermatitis, Atopic; Dermatitis, Contact; Dinitrofluorobenzene; Disease Models, Animal; Humans; Imiquimod; Inflammation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Programmed Cell Death 1 Ligand 2 Protein; Psoriasis; Skin; Th1 Cells; Th17 Cells; Th2 Cells | 2022 |
Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis.
Topics: Adult; Aged; Aminoquinolines; Animals; Cells, Cultured; Chemokine CCL20; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Female; Humans; Imiquimod; Interleukin-17; Keratinocytes; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Psoriasis; Receptors, CCR6; Recombinant Proteins; Serum Amyloid A Protein; Skin; Th17 Cells; Up-Regulation | 2017 |
CD100-Plexin-B2 Promotes the Inflammation in Psoriasis by Activating NF-κB and the Inflammasome in Keratinocytes.
Topics: Animals; Antigens, CD; Biopsy; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Gene Expression Regulation; Healthy Volunteers; Humans; Imiquimod; Inflammasomes; Keratinocytes; Mice, Inbred BALB C; Nerve Tissue Proteins; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Primary Cell Culture; Protein Binding; Psoriasis; RNA, Small Interfering; Semaphorins; Signal Transduction; Skin | 2018 |
IL-17A induces heterogeneous macrophages, and it does not alter the effects of lipopolysaccharides on macrophage activation in the skin of mice.
Topics: Animals; Cell Differentiation; CX3C Chemokine Receptor 1; Dermatitis, Atopic; Disease Models, Animal; Gene Expression Regulation; Imiquimod; Interleukin-17; Lectins, C-Type; Lipopolysaccharides; Macrophage Activation; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Transgenic; Nitric Oxide Synthase Type II; Phosphoproteins; Psoriasis; Receptors, Cell Surface; Signal Transduction; Skin; STAT1 Transcription Factor; STAT3 Transcription Factor | 2017 |
Macrophages express βKlotho in skin lesions of psoriatic patients and the skin of imiquimod-treated mice.
Topics: Adult; Aged; Animals; Antibodies, Neutralizing; Case-Control Studies; Dermatitis, Atopic; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Immunohistochemistry; Interleukin-17; Klotho Proteins; Macrophages; Male; Membrane Proteins; Mice; Middle Aged; Psoriasis; Skin | 2018 |
Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cantharidin; Cryotherapy; Dermatitis, Atopic; Drug Resistance, Viral; Drug Substitution; Humans; Imiquimod; Immunosuppressive Agents; Interleukin-4 Receptor alpha Subunit; Male; Molluscum Contagiosum; Molluscum contagiosum virus; Treatment Outcome | 2019 |
Dietary supplementation of omega-3 fatty acid eicosapentaenoic acid does not ameliorate pruritus in murine models of atopic dermatitis and psoriasis.
Topics: Animals; Antigens, Dermatophagoides; Dermatitis, Atopic; Dietary Supplements; Disease Models, Animal; Eicosanoids; Eicosapentaenoic Acid; Humans; Imiquimod; Lipid Metabolism; Male; Mice; Pruritus; Psoriasis; Skin; Treatment Outcome | 2019 |
Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice.
Topics: Aminoquinolines; Animals; Axitinib; Dermatitis, Atopic; Disease Models, Animal; Epidermis; Humans; Imidazoles; Imiquimod; Indazoles; Mice; Pruritus; Psoriasis; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2016 |
Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis.
Topics: Aminoquinolines; Animals; Chemokine CCL5; Dermatitis, Atopic; Filaggrin Proteins; Imiquimod; Intermediate Filament Proteins; Mast Cells; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; STAT6 Transcription Factor; Th17 Cells; Th2 Cells; Toll-Like Receptor 7; Ubiquitin-Protein Ligases | 2017 |
Restoring tacrolimus-induced impaired barrier function.
Topics: Aminoquinolines; Animals; Antimicrobial Cationic Peptides; beta-Defensins; Cathelicidins; Cell Membrane; Cell Membrane Permeability; Dermatitis, Atopic; Epidermal Cells; Epidermis; Humans; Imiquimod; Immunosuppressive Agents; Interleukin-1alpha; Lipid Metabolism; Mice; Mice, Transgenic; Models, Animal; Receptors, Interleukin-1; Signal Transduction; Tacrolimus | 2011 |
[Topical immunomodulators in dermatology].
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Asthma; Autoimmune Diseases; Bowen's Disease; Child; Cyclopropanes; Dermatitis, Atopic; Dinitrochlorobenzene; Female; Follow-Up Studies; Herpes Simplex; Humans; Imidazoles; Imiquimod; Immunity, Cellular; Immunocompromised Host; Immunoglobulin A; Immunosuppressive Agents; Lichen Sclerosus et Atrophicus; Male; Molluscum Contagiosum; Papillomavirus Infections; Precancerous Conditions; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Time Factors; Warts | 2003 |
Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Antineoplastic Agents; Antiviral Agents; Cells, Cultured; Cytoplasmic Granules; Dermatitis, Atopic; Flow Cytometry; Humans; Imiquimod; Ionomycin; Membrane Glycoproteins; Perforin; Pore Forming Cytotoxic Proteins; Receptors, Cell Surface; T-Lymphocytes, Cytotoxic; Tetradecanoylphorbol Acetate; Toll-Like Receptor 7; Toll-Like Receptors | 2004 |
[Therapy-resistant disseminated verrucae in an atopic patient with cellular immunodeficiency--successful topical treatment with imiquimod].
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Dermatitis, Atopic; Humans; Imiquimod; Immunity, Cellular; Immunologic Deficiency Syndromes; Male; Warts | 2003 |